English

XERIS PHARMACEUTICALS INC

EDGAR

XERS Quarterly report (10-Q) · filed 2021-08-05

17 filing records in this dataset, filed from 2016-12-30 to 2021-08-05. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

8.8 million USD

2021 Q2 · USD

Exact inputs and evidence

Revenue: 8800000 USD Source

Operating margin

-293.03%

2021 Q2 · %

Exact inputs and evidence

Operating Income: -25787000 USD Source
Revenue: 8800000 USD Source

Operating cash flow

-20 million USD

2021 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -43978000 USD Source
Operating Cash Flow: -23956000 USD Source

Free cash flow

-20.2 million USD

2021 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -43978000 USD Source
Operating Cash Flow: -23956000 USD Source
Capital Expenditure: 647000 USD Source
Capital Expenditure: 429000 USD Source

Cash and cash equivalents: 63.6 million USD 2021-06-30 Source
Exact value

63599000 USD
Long-term debt including current maturities: 87.5 million USD 2021-06-30 Source
Exact value

87478000 USD
Shares outstanding: 66.5 million shares 2021-06-30 Source
Exact value

66497370 shares

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

33.4 million USD

2020-07-01 – 2021-06-30

Exact inputs and evidence

Revenue: 9404000 USD · 2020-07-01 – 2020-09-30 Source
Revenue: 20155000 USD · 2020-01-01 – 2020-12-31 Source
Revenue: 13100000 USD · 2020-01-01 – 2020-09-30 Source
Revenue: 8100000 USD · 2021-01-01 – 2021-03-31 Source
Revenue: 8800000 USD · 2021-04-01 – 2021-06-30 Source

Net income

-83.8 million USD

2020-07-01 – 2021-06-30

Exact inputs and evidence

Net income: -16000000 USD · 2020-07-01 – 2020-09-30 Source
Net income: -91140000 USD · 2020-01-01 – 2020-12-31 Source
Net income: -69283000 USD · 2020-01-01 – 2020-09-30 Source
Net income: -18411000 USD · 2021-01-01 – 2021-03-31 Source
Net income: -27515000 USD · 2021-04-01 – 2021-06-30 Source

Operating cash flow

-71.8 million USD

2020-07-01 – 2021-06-30

Exact inputs and evidence

Operating cash flow: -69689000 USD · 2020-01-01 – 2020-09-30 Source
Operating cash flow: -52704000 USD · 2020-01-01 – 2020-06-30 Source
Operating cash flow: -80558000 USD · 2020-01-01 – 2020-12-31 Source
Operating cash flow: -69689000 USD · 2020-01-01 – 2020-09-30 Source
Operating cash flow: -23956000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: -43978000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -23956000 USD · 2021-01-01 – 2021-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2021-08-05.

Financial data available through: 2020-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2020-12-31
Operating income: 5 of 11 periods available· newest 2020-12-31
Net income: 5 of 11 periods available· newest 2020-12-31
Operating cash flow: 5 of 11 periods available· newest 2020-12-31
Capital expenditure: 5 of 11 periods available· newest 2020-12-31
Total assets: 5 of 11 periods available· newest 2020-12-31
Total liabilities: 5 of 11 periods available· newest 2020-12-31
Current assets: 5 of 11 periods available· newest 2020-12-31
Current liabilities: 5 of 11 periods available· newest 2020-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2020-12-31
Long-term debt including current maturities: 4 of 11 periods available· newest 2020-12-31
Shares outstanding: 3 of 11 periods available· newest 2020-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+1,138.8%

Prior period

USD 1.63 million

2019-01-01 – 2019-12-31
Current period

USD 20.16 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

20155000 − 1627000 = 18528000 USD

1627000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
20155000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · XERIS PHARMACEUTICALS INC · 2020-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Year-over-year change in Revenue: 18528000 USD Concept: fundies:Revenue Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 20155000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630221000026/xers-20201231.htm#1203002 Filing: 000134630221000026 Input fundies:Revenue: 1627000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630221000026/xers-20201231.htm#1204189 Filing: 000134630221000026
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 34.44 million

Prior period

−USD 125.58 million

2019-01-01 – 2019-12-31
Current period

−USD 91.14 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

-91140000 − -125580000 = 34440000 USD

-125580000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
-91140000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · XERIS PHARMACEUTICALS INC · 2020-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Year-over-year change in Net income: 34440000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -91140000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630221000026/xers-20201231.htm#1336684 Filing: 000134630221000026 Input fundies:NetIncome: -125580000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630221000026/xers-20201231.htm#1337749 Filing: 000134630221000026
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 23.79 million

Prior period

−USD 104.35 million

2019-01-01 – 2019-12-31
Current period

−USD 80.56 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

-80558000 − -104346000 = 23788000 USD

-104346000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
-80558000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · XERIS PHARMACEUTICALS INC · 2020-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Year-over-year change in Operating cash flow: 23788000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -80558000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630221000026/xers-20201231.htm#1372506 Filing: 000134630221000026 Input fundies:OperatingCashFlow: -104346000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630221000026/xers-20201231.htm#1373479 Filing: 000134630221000026
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+USD 730,000

Prior period

−USD 1.11 million

2019-01-01 – 2019-12-31
Current period

−USD 377,000

2020-01-01 – 2020-12-31

Exact inputs and evidence

-377000 − -1107000 = 730000 USD

-1107000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
-377000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · XERIS PHARMACEUTICALS INC · 2020-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Year-over-year change in Capital expenditure: 730000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: -377000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630221000026/xers-20201231.htm#1375140 Filing: 000134630221000026 Input fundies:CapitalExpenditure: -1107000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630221000026/xers-20201231.htm#1376025 Filing: 000134630221000026
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2020 2020-01-01 – 2020-12-31

Revenue USD 20.16 million 100% of revenue
Cost of revenue USD 9.33 million 46% of revenue
Operating expenses USD 94.65 million 470% of revenue
Other operating costs Derived −USD 280,000 −1.4% of revenue
Operating income −USD 83.55 million −415% of revenue
Tax, interest and other Derived USD 7.59 million 38% of revenue
Net income −USD 91.14 million −452% of revenue

Cash

Operating cash flow −USD 80.56 million −400% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 25,064% of revenue.
2017 Operating loss: operating costs were 166,531% of revenue.
2018 Not shown: operating income or net income is not reported.
2019 Operating loss: operating costs were 7,622% of revenue.
2020 Operating loss: operating costs were 515% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	53000	13284000 Derived	-13231000	-22000 Derived	-13209000	-16122000 Derived	Source 2016-01-01 – 2016-12-31: 53000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -13231000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -13209000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -16087000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 35000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	16000	26645000 Derived	-26629000	-75000 Derived	-26554000	Unavailable	Source 2017-01-01 – 2017-12-31: 16000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -26629000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -26554000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -24663000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: -700000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	0	59344000 Derived	-59344000	736000 Derived	-60080000	Unavailable	Source 2018-01-01 – 2018-12-31: 0 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -59344000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -60080000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -56279000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: -1510000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	1627000	124007000 Derived	-122380000	3200000 Derived	-125580000	Unavailable	Source 2019-01-01 – 2019-12-31: 1627000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -122380000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -125580000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -104346000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: -1107000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	20155000	103701000 Derived	-83546000	7594000 Derived	-91140000	Unavailable	Source 2020-01-01 – 2020-12-31: 20155000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -83546000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -91140000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -80558000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: -377000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 20.2M 2020

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	53000	Revenue: 53000 Open source
20172017-12-31	Revenue	16000	Revenue: 16000 Open source
20182018-12-31	Revenue	0	Revenue: 0 Open source
20192019-12-31	Revenue	1627000	Revenue: 1627000 Open source
20202020-12-31	Revenue	20155000	Revenue: 20155000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

1,138.8% 2020

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 53000 Open source
20172017-12-31	Year over year	-69.8%	Revenue: 16000 Open source Revenue: 53000 Open source
20182018-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 16000 Open source
20192019-12-31	Year over year	No prior comparable period	Revenue: 1627000 Open source Revenue: 0 Open source
20202020-12-31	Year over year	1,138.8%	Revenue: 20155000 Open source Revenue: 1627000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -414.5% 2020

Net margin -452.2% 2020

Free cash flow margin -30,418.9% 2016

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-24,964.2%	Operating Income: -13231000 Open source Revenue: 53000 Open source
20172017-12-31	Operating margin	-166,431.3%	Operating Income: -26629000 Open source Revenue: 16000 Open source
20182018-12-31	Operating margin	Not reported	Operating Income: -59344000 Open source Revenue: 0 Open source
20192019-12-31	Operating margin	-7,521.8%	Operating Income: -122380000 Open source Revenue: 1627000 Open source
20202020-12-31	Operating margin	-414.5%	Operating Income: -83546000 Open source Revenue: 20155000 Open source
20162016-12-31	Net margin	-24,922.6%	Net Income: -13209000 Open source Revenue: 53000 Open source
20172017-12-31	Net margin	-165,962.5%	Net Income: -26554000 Open source Revenue: 16000 Open source
20182018-12-31	Net margin	Not reported	Net Income: -60080000 Open source Revenue: 0 Open source
20192019-12-31	Net margin	-7,718.5%	Net Income: -125580000 Open source Revenue: 1627000 Open source
20202020-12-31	Net margin	-452.2%	Net Income: -91140000 Open source Revenue: 20155000 Open source
20162016-12-31	Free cash flow margin	-30,418.9%	Revenue: 53000 Open source Operating Cash Flow: -16087000 Open source Capital Expenditure: 35000 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 16000 Open source Operating Cash Flow: -24663000 Open source Capital Expenditure: -700000 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -56279000 Open source Capital Expenditure: -1510000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 1627000 Open source Operating Cash Flow: -104346000 Open source Capital Expenditure: -1107000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 20155000 Open source Operating Cash Flow: -80558000 Open source Capital Expenditure: -377000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -80.6M 2020

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-16087000	Operating Cash Flow: -16087000 Open source
20172017-12-31	Operating cash flow	-24663000	Operating Cash Flow: -24663000 Open source
20182018-12-31	Operating cash flow	-56279000	Operating Cash Flow: -56279000 Open source
20192019-12-31	Operating cash flow	-104346000	Operating Cash Flow: -104346000 Open source
20202020-12-31	Operating cash flow	-80558000	Operating Cash Flow: -80558000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -16.1M 2016

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-16122000	Operating Cash Flow: -16087000 Open source Capital Expenditure: 35000 Open source
20172017-12-31	Free cash flow	Unavailable	Operating Cash Flow: -24663000 Open source Capital Expenditure: -700000 Open source
20182018-12-31	Free cash flow	Unavailable	Operating Cash Flow: -56279000 Open source Capital Expenditure: -1510000 Open source
20192019-12-31	Free cash flow	Unavailable	Operating Cash Flow: -104346000 Open source Capital Expenditure: -1107000 Open source
20202020-12-31	Free cash flow	Unavailable	Operating Cash Flow: -80558000 Open source Capital Expenditure: -377000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

78.8% 2020

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	7.7%	Total Liabilities: 2569000 Open source Total Assets: 33533000 Open source
20172017-12-31	Liabilities / assets	11%	Total Liabilities: 4950000 Open source Total Assets: 44998000 Open source
20182018-12-31	Liabilities / assets	37.2%	Total Liabilities: 44622000 Open source Total Assets: 120028000 Open source
20192019-12-31	Liabilities / assets	86.8%	Total Liabilities: 94551000 Open source Total Assets: 108987000 Open source
20202020-12-31	Liabilities / assets	78.8%	Total Liabilities: 125390000 Open source Total Assets: 159151000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.4× 2020

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	13.13×	Current Assets: 33174000 Open source Current Liabilities: 2527000 Open source
20172017-12-31	Current assets / current liabilities	9.06×	Current Assets: 44053000 Open source Current Liabilities: 4860000 Open source
20182018-12-31	Current assets / current liabilities	11.59×	Current Assets: 117899000 Open source Current Liabilities: 10172000 Open source
20192019-12-31	Current assets / current liabilities	3.2×	Current Assets: 87483000 Open source Current Liabilities: 27338000 Open source
20202020-12-31	Current assets / current liabilities	5.4×	Current Assets: 152212000 Open source Current Liabilities: 28207000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 13.21 million Exact value Exact value: -13209000 USD 2016-01-01 – 2016-12-31: -13209000 USD Inspect Net Income Open source Share or cite Citation for Net Income · XERIS PHARMACEUTICALS INC · 2016-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Net Income: -13209000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13209000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000119312519033935/xers-20180930.xml#896118 Filing: 000119312519033935 The citation records this snapshot. The page link may show a newer release later.	−USD 16.09 million Exact value Exact value: -16087000 USD 2016-01-01 – 2016-12-31: -16087000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · XERIS PHARMACEUTICALS INC · 2016-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Operating Cash Flow: -16087000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16087000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000119312519033935/xers-20180930.xml#895849 Filing: 000119312519033935 The citation records this snapshot. The page link may show a newer release later.	USD 35,000 Exact value Exact value: 35000 USD 2016-01-01 – 2016-12-31: 35000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · XERIS PHARMACEUTICALS INC · 2016-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Capital Expenditure: 35000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 35000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000119312519033935/xers-20180930.xml#897496 Filing: 000119312519033935 The citation records this snapshot. The page link may show a newer release later.	−USD 16.12 million Calculation and evidence -16087000 − 35000 USD Exact free cash flow: -16122000 USD 2016-01-01 – 2016-12-31: -16087000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 35000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · XERIS PHARMACEUTICALS INC · 2016-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Free cash flow: -16122000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16087000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000119312519033935/xers-20180930.xml#895849 Filing: 000119312519033935 Input fundies:CapitalExpenditure: 35000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000119312519033935/xers-20180930.xml#897496 Filing: 000119312519033935 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 26.55 million Exact value Exact value: -26554000 USD 2017-01-01 – 2017-12-31: -26554000 USD Inspect Net Income Open source Share or cite Citation for Net Income · XERIS PHARMACEUTICALS INC · 2017-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Net Income: -26554000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -26554000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630219000009/xers-20181231.xml#115407 Filing: 000134630219000009 The citation records this snapshot. The page link may show a newer release later.	−USD 24.66 million Exact value Exact value: -24663000 USD 2017-01-01 – 2017-12-31: -24663000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · XERIS PHARMACEUTICALS INC · 2017-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Operating Cash Flow: -24663000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24663000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630219000009/xers-20181231.xml#114983 Filing: 000134630219000009 The citation records this snapshot. The page link may show a newer release later.	Unavailable The mapped spending value is negative, so its direction is unclear. Source Inspect Capital Expenditure Open source	Unavailable Capital expenditure has a negative mapped value; spending direction is unclear.
2018 2018-01-01 – 2018-12-31	−USD 60.08 million Exact value Exact value: -60080000 USD 2018-01-01 – 2018-12-31: -60080000 USD Inspect Net Income Open source Share or cite Citation for Net Income · XERIS PHARMACEUTICALS INC · 2018-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Net Income: -60080000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -60080000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630220000007/xers-20191231.xml#163743 Filing: 000134630220000007 The citation records this snapshot. The page link may show a newer release later.	−USD 56.28 million Exact value Exact value: -56279000 USD 2018-01-01 – 2018-12-31: -56279000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · XERIS PHARMACEUTICALS INC · 2018-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Operating Cash Flow: -56279000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -56279000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630220000007/xers-20191231.xml#163318 Filing: 000134630220000007 The citation records this snapshot. The page link may show a newer release later.	Unavailable The mapped spending value is negative, so its direction is unclear. Source Inspect Capital Expenditure Open source	Unavailable Capital expenditure has a negative mapped value; spending direction is unclear.
2019 2019-01-01 – 2019-12-31	−USD 125.58 million Exact value Exact value: -125580000 USD 2019-01-01 – 2019-12-31: -125580000 USD Inspect Net Income Open source Share or cite Citation for Net Income · XERIS PHARMACEUTICALS INC · 2019-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Net Income: -125580000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -125580000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630221000026/xers-20201231.htm#1337749 Filing: 000134630221000026 The citation records this snapshot. The page link may show a newer release later.	−USD 104.35 million Exact value Exact value: -104346000 USD 2019-01-01 – 2019-12-31: -104346000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · XERIS PHARMACEUTICALS INC · 2019-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Operating Cash Flow: -104346000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -104346000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630221000026/xers-20201231.htm#1373479 Filing: 000134630221000026 The citation records this snapshot. The page link may show a newer release later.	Unavailable The mapped spending value is negative, so its direction is unclear. Source Inspect Capital Expenditure Open source	Unavailable Capital expenditure has a negative mapped value; spending direction is unclear.
2020 2020-01-01 – 2020-12-31	−USD 91.14 million Exact value Exact value: -91140000 USD 2020-01-01 – 2020-12-31: -91140000 USD Inspect Net Income Open source Share or cite Citation for Net Income · XERIS PHARMACEUTICALS INC · 2020-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Net Income: -91140000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -91140000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630221000026/xers-20201231.htm#1336684 Filing: 000134630221000026 The citation records this snapshot. The page link may show a newer release later.	−USD 80.56 million Exact value Exact value: -80558000 USD 2020-01-01 – 2020-12-31: -80558000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · XERIS PHARMACEUTICALS INC · 2020-12-31 XERIS PHARMACEUTICALS INC (edgar:1346302) Operating Cash Flow: -80558000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:40:22Z Snapshot: 7548049bb1e55d8089886fe13b09afd7703b715c23e4e7d610ac818aed71a50f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1346302/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -80558000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630221000026/xers-20201231.htm#1372506 Filing: 000134630221000026 The citation records this snapshot. The page link may show a newer release later.	Unavailable The mapped spending value is negative, so its direction is unclear. Source Inspect Capital Expenditure Open source	Unavailable Capital expenditure has a negative mapped value; spending direction is unclear.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

17 filings · 1,105 latest values · 1,135 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001346302, 1346302, XERS, edgar:1346302

Also known as XERIS PHARMACEUTICALS INC, XERIS PHARMACEUTICALS, INC.

XERIS PHARMACEUTICALS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2020 2020-01-01 – 2020-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation